

Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to \$20.3 billion. For more information, visit www.tevapharm.com. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.

Primary IR Contact

Investor Relations

Phone: (215) 591-3034**E-mail:**

TevaIRus@tevapharm.com

Recent Headlines

May 17, 2017

Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference

May 17, 2017

Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting

May 15, 2017


Teva Announces Launch of Generic Glumetza® in the United States

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 2.5



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	1.13	1.14	1.15
QTR	Sep 17	1.24	1.28	1.25
QTR	Dec 17	1.37	1.40	1.38
QTR	Mar 18	1.14	1.18	1.20
FY	Dec 17	4.77	4.81	4.77
FY	Dec 18	4.71	4.78	4.78

SEC Filings

Filing Date	Form
05/17/17	6-K
05/17/17	6-K
05/15/17	6-K
05/15/17	6-K

Financial Reports

Date	
11/14/16	Third Quarter 2016 Earnings Press Release

Presentations

Date	
05/11/17	Teva First Quarter Results 2017 Presentation

Corporate Officers

Erez Vigodman

President and CEO

Iris Beck-Codner

Senior Vice President, Chief Communications Officer

Dr. Carlo De Notaristefani

President and Chief Executive Officer, Global Operations

Eyal Desheh

Group Executive Vice President, Chief Financial Officer

Richard S. Egosi

Group Executive Vice President, Chief Legal Officer and Company Secretary
Executive Vice President, Chief Internal Auditor

Dr. Michael Hayden

President of Global R&D and Chief Scientific Officer

Dr. Rob Koremans

President and CEO, Global Specialty Medicines

Sigurdur (Siggi) Olafsson

President and Chief Executive Officer, Global Generic Medicines Group

Mark Sabag

Group Executive Vice President, Human Resources

Timothy R. Wright

Executive Vice President, Business Development, Strategy and Commercial Innovation

Nir Baron